|
In € millions, except earnings per share and dividend (in €) |
2013 | 2014 | 2015
|
2016 |
2017 |
|---|---|---|---|---|---|
|
Order intake |
12,928 | 14,363 | 18,880 | 16,514 | 14,920 |
|
Order book at end of period |
24,469 | 27,885 | 32,292 | 33,530 | 31,914 |
Sales |
12,698 |
12,974 |
14,063 |
14,885 |
15,795 |
| Total change | + 0.3% | + 2.2% | + 8.4% | + 5.8% | + 6.1% |
| Organic change | + 3.3% | - 1.2% | + 4.5% | + 6.8% | + 7.2% |
EBIT (2) |
1,011 |
985 |
1,216 |
1,354 |
1,543 |
| In % of sales | 8.0% | 7.6% | 8.6% | 9.1% | 9.8% |
Adjusted net income , Group share (2) |
642 |
562 |
809 |
897 |
982 |
Consolidated net income, Group share |
573 | 714 | 765 | 946 | 822 |
Adjusted net income Group share, per share (EPS)(2) |
3.20 |
2.75 |
3.89 |
4.25 |
4.64 |
Dividend per share |
1.12 | 1.12 | 1.36 | 1.60 | 1.75(2) |
Free operating cash-flow (2) |
477 |
501 |
1,110 |
954 |
1,365 |
Net cash position at end of period |
1,077 | 1,006 | 1,978 | 2,366 | 2,971 |
Self-funded R&D(4) |
638 | 675 | 707 |
743
|
813 |
Consolidated headcount at year-end |
59,467 | 61,709 | 62,194 | 64,071 | 64,860 |
- (1) Non-strictly accounting measures. See definitions in the corresponding reference documents.
- (2) Proposed to the 23 May 2018 AGM
- (3) Including capitalized R&D
Contact
Investors relations
+33 (0) 1 57 77 89 02
ir@thalesgroup.com